Low-dose versus high-dose dexamethasone for hospitalized patients with COVID-19 pneumonia: A randomized clinical trial.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
11
07
2022
accepted:
09
09
2022
entrez:
3
10
2022
pubmed:
4
10
2022
medline:
6
10
2022
Statut:
epublish
Résumé
Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of dexamethasone in hospitalized patients with COVID-19 pneumonia. We conducted a single-center, randomized, clinical trial involving hospitalized patients with COVID-19 pneumonia. Participants were randomized 1:1 to dexamethasone 6 mg daily or dexamethasone 20 mg daily, and were stratified by the WHO-Ordinal Scale for Clinical Improvement (OSCI). The primary outcome was clinical improvement equal to or greater than 2 points by OSCI on day 28. Secondary outcomes were 28-day mortality, intensive care unit-free days, and ventilator-free days on day 28. Of the 107 patients who enrolled and completed the follow up, 55 patients enrolled in the low-dose group and 52 patients enrolled in the high-dose group. Treatment with dexamethasone 20 mg daily compared with dexamethasone 6 mg daily did not result in better clinical improvement based on OSCI on day 28 (71.2% vs. 78.2%; odds ratio, 1.45 [0.55-3.86]; p = 0.403). For participants who required high-flow oxygen or noninvasive ventilation at randomization, the 6-mg group had better survival than the 20-mg group on day 28 (100% vs. 57.1%; p = 0.025). Although more participants in the 6-mg group received immune modulators (40% vs. 21.2%; p = 0.035), 50% of death cases in the 20-mg group who required high-flow oxygen or noninvasive ventilation at randomization received immune modulators. Dexamethasone 20 mg daily did not result in better clinical outcome improvement, and was probably associated with higher 28-day mortality in patients on high-flow oxygen or noninvasive ventilation, compared with dexamethasone 6 mg daily. Clinialtrials.gov number, NCT04707534, registered January 13, 2021.
Sections du résumé
BACKGROUND
Dexamethasone 6 mg daily for 10 days is the recommended treatment for patients with severe or critical coronavirus disease 2019 (COVID-19). The evidence on the benefit of high-dose dexamethasone is limited. The goal of this study was to assess the effects of 6 mg daily vs. 20 mg daily of dexamethasone in hospitalized patients with COVID-19 pneumonia.
METHODS
We conducted a single-center, randomized, clinical trial involving hospitalized patients with COVID-19 pneumonia. Participants were randomized 1:1 to dexamethasone 6 mg daily or dexamethasone 20 mg daily, and were stratified by the WHO-Ordinal Scale for Clinical Improvement (OSCI). The primary outcome was clinical improvement equal to or greater than 2 points by OSCI on day 28. Secondary outcomes were 28-day mortality, intensive care unit-free days, and ventilator-free days on day 28.
RESULTS
Of the 107 patients who enrolled and completed the follow up, 55 patients enrolled in the low-dose group and 52 patients enrolled in the high-dose group. Treatment with dexamethasone 20 mg daily compared with dexamethasone 6 mg daily did not result in better clinical improvement based on OSCI on day 28 (71.2% vs. 78.2%; odds ratio, 1.45 [0.55-3.86]; p = 0.403). For participants who required high-flow oxygen or noninvasive ventilation at randomization, the 6-mg group had better survival than the 20-mg group on day 28 (100% vs. 57.1%; p = 0.025). Although more participants in the 6-mg group received immune modulators (40% vs. 21.2%; p = 0.035), 50% of death cases in the 20-mg group who required high-flow oxygen or noninvasive ventilation at randomization received immune modulators.
CONCLUSIONS
Dexamethasone 20 mg daily did not result in better clinical outcome improvement, and was probably associated with higher 28-day mortality in patients on high-flow oxygen or noninvasive ventilation, compared with dexamethasone 6 mg daily.
TRIAL REGISTRATION
Clinialtrials.gov number, NCT04707534, registered January 13, 2021.
Identifiants
pubmed: 36190994
doi: 10.1371/journal.pone.0275217
pii: PONE-D-22-19410
pmc: PMC9529091
doi:
Substances chimiques
Dexamethasone
7S5I7G3JQL
Oxygen
S88TT14065
Banques de données
ClinicalTrials.gov
['NCT04707534']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0275217Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet Respir Med. 2021 Aug;9(8):909-923
pubmed: 33812494
Intensive Care Med. 2022 Jan;48(1):45-55
pubmed: 34757439
JAMA. 2020 Oct 6;324(13):1307-1316
pubmed: 32876695
JAMA Netw Open. 2020 Sep 1;3(9):e2022310
pubmed: 32965502
J Cardiothorac Vasc Anesth. 2022 Sep;36(9):3576-3586
pubmed: 35715291
BMC Musculoskelet Disord. 2016 Jul 16;17:293
pubmed: 27424036
JAMA. 2021 Nov 9;326(18):1807-1817
pubmed: 34673895
N Engl J Med. 2006 Apr 20;354(16):1671-84
pubmed: 16625008
J Intensive Care Med. 2022 Apr;37(4):491-499
pubmed: 34898320
Eur Respir J. 2022 Aug 4;60(2):
pubmed: 34916266
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
JAMA Netw Open. 2021 Jul 1;4(7):e2116901
pubmed: 34255046
Pharmacol Rep. 2022 Feb;74(1):229-240
pubmed: 34837648
Lancet. 2021 May 01;397(10285):1637-1645
pubmed: 33933206
Lancet Respir Med. 2021 Dec;9(12):1407-1418
pubmed: 34480861
JAMA. 2020 Oct 6;324(13):1330-1341
pubmed: 32876694
JAMA. 2020 Oct 20;324(15):1499-1500
pubmed: 33001179
Lancet Respir Med. 2021 Aug;9(8):e77
pubmed: 34090607
JAMA Intern Med. 2022 Sep 1;182(9):906-916
pubmed: 35788622